http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Efficient Killing Effect of Osteosarcoma Cells by Cinobufacini and Cisplatin in Combination
Huang, Tao,Gong, Wei-Hua,Li, Xiu-Cheng,Zou, Chun-Ping,Jiang, Guang-Jian,Li, Xu-Hui,Qian, Hao Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.6
Purpose: To study the killing effects on osteosarcoma cells of cinobufacini and cisplatin in combination and the related mechanisms so as to explore the chemotherapeutic method with integrated traditional Chinese and Western medicines. Methods: Cinobufacini and cisplatin were applied to OS732 cells singly or jointly and survival rates were measured by MTT assay. Changes in cellular shape were observed with inverted phase contrast and fluorescence microscopy and apoptosis rates were analyzed with flow cytometry (FCM). Immunocytochemistry were used to examine the Fas expression of OS732 cells. Results: The combination of cinobufacini and cisplatin had the effect of up-regulating Fas expression and inducing apoptosis. The survival rate of combined application of 100 ${\mu}g/ml$ cinobufacini and 1 ${\mu}g/ml$ cisplatin on OS-732 cells was significantly lower than with either of the agents alone (p<0.01). Changes in cellular shape and apoptotic rates also indicated the apoptosis-inducing effects of combined application were much enhanced. Conclusion: The combination of cinobufacini and cisplatin demonstrated strong killing effects on OS-732 cells which might be related to up-regulation of Fas expression.
Pyrophosphate-triggered nanoaggregates with aggregation-induced emission
Li, Chun-Tao,Xu, You-Liang,Yang, Jian-Gong,Chen, Yong,Kim, Hyeong Seok,Cao, Qian-Yong,Kim, Jong Seung Elsevier Sequoia 2017 Sensors and actuators. B Chemical Vol.251 No.-
<P><B>Abstract</B></P> <P>A novel tetraphenylethene-based probe bearing bis-imidazolium anion donors is herein reported for pyrophosphate anion recognition. This probe can self-assemble finite, small sphere nanoaggregates with very weak emission in aqueous solution, and changes into large rod-like nanoaggregates with strong aggregation-induced emission upon binding with the pyrophosphate anion.</P> <P><B>Highlights</B></P> <P> <UL> <LI> A bis-imidazolium functionalized tetraphenylethene probe was prepared. </LI> <LI> This probe self-assemble finite small sphere nanoaggregates in aqueous solution. </LI> <LI> The probe can recognize pyrophosphate anion with strong aggregation-induced emission. </LI> <LI> The probe/pyrophosphate assembly can fluorescence assay alkaline phosphatase. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>A novel nanoaggregates for recognition of pyrophosphate anion with aggregation-induced emission in pure aqueous solution is introduced.</P> <P>[DISPLAY OMISSION]</P>
Oxaliplatin Sensitizes OS Cells to TRAIL-induced Apoptosis Via Down-regulation of Mcl1
Huang, Tao,Gong, Wei-Hua,Li, Xiu-Cheng,Zou, Chun-Ping,Jiang, Guang-Jian,Li, Xu-Hui,Qian, Hao Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.7
Purpose: To investigate the killing effect on OS cells of a combination of oxaliplatin and TRAIL and related molecular mechanisms. Methods: TRAIL and oxaliplatin were applied to OS732 cells singly or jointly and survival inhibition rates were measured by MTT assay, changes of cellular shape being assessed with inverted phase contrast and fluorescence microscopy. Apoptotic rates were analyzed by flow cytometry (FCM) and immunocytochemistry was used to examine Mcl1 expression of OS732 cells. Results: The survival inhibition rate of combined application of $100{\mu}g/ml$ TRAIL and $1{\mu}g/ml$ oxaliplatin on OS-732 cells was significantly higher than that of either agent singly (p<0.01). Changes of cellular shape and apoptotic rates also indicated apoptosis-inducing effects of combined application to be much stronger than those of individual application. Oxaliplatin had the effect of down-regulating Mcl1 expression and sensitizing OS cells to TRAIL-induced apoptosis. Conclusion: A combination of TRAIL and oxaliplatin exerts strong killing effects on OS-732 cells which might be related to down-regulation of Mcl1 expression.
The 2518 A/G Polymorphism in the MCP-1 Gene and Cancer Risk: A Meta-analysis
Jia, Liu-Qun,Shen, Yong-Chun,Guo, Shu-Jin,Hu, Qian-Jing,Pang, Cai-Shuang,Wang, Tao,Chen, Lei,Wen, Fu-Qiang Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.6
Background: The 2518 A/G polymorphism in the MCP-1 gene has been extensively studied for association swith cancer; however, results from replication studies have been inconsistent. The aim of this investigation was to determine links with risk of cancer by meta-analysis. Methods: We searched Pubmed, Embase, CNKI, Weipu and Wanfang databases, covering all case-control studies until March, 2013. Statistical analyses were performed using the Revman 5.0 software. Results: A total of 11 case-control studies met our inclusion criteria, including 1,422 cases and 2,237 controls. The results indicated that the MCP-1 2518 gene polymorphism had no association with cancer risk overall (GG vs.GA+ AA: OR = 0.89, 95%CI = 0.61-1.28, P = 0.52). However, in the subgroup analysis by ethnicity, a decrease of cancer risk was found in Asian populations (GG vs.GA+ AA: OR = 0.79, 95%CI = 0.63-0.99, P = 0.04). Conclusion: This meta-analysis suggested that the 2518A/G polymorphism of MCP-1 gene is associated with risk of cancer among Asian, but not in Caucasian populations.
Man Zhang,Su‑Su Li,Qiao‑Mei Xie,Jian‑Hua Xu,Xiu‑Xiu Sun,Fa‑Ming Pan,Sheng‑Qian Xu,Sheng‑Xiu Liu,Jin‑Hui Tao,Shuang Liu,Jing Cai,Pei‑Ling Chen,Long Qian,Chun‑Huai Wang,Chun‑Mei Liang,Hai‑Liang Huang,Ha 한국유전학회 2018 Genes & Genomics Vol.40 No.10
Although the current glucocorticoids (GCs) treatment for systemic lupus erythematosus (SLE) is effective to a certain extent, the difference in therapeutic effect between patients is still a widespread problem. Some patients can have repeated attacks that greatly diminish their quality of life. This study was conducted to investigate the relationship between HSP90AA2 polymorphisms and disease susceptibility, GCs efficacy and health-related quality of life (HRQoL) in Chinese SLE patients. A case–control study was performed in 470 SLE patients and 470 normal controls. Then, 444 patients in the case group were followed up for 12 weeks to observe efficacy of GCs and improvement of HRQoL. Two single nucleotide polymorphisms (SNPs) of HSP90AA2 were selected for genotyping: rs1826330 and rs6484340. HRQoL was assessed using the SF-36 questionnaire. The minor T allele of rs1826330 and the TT haplotype formed by rs1826330 and rs6484340 showed associations with decreased SLE risk (T allele: PBH = 0.022; TT haplotype: PBH = 0.033). A significant association between rs6484340 and improvement of HRQoL was revealed in the follow-up study. Five subscales of SF-36 were appeared to be influenced by rs6484340: total score of SF-36 (additive model: PBH = 0.026), physical function (additive model: PBH = 0.026), rolephysical (recessive model: PBH = 0.041), mental health (dominant model: PBH = 0.047), and physical component summary (additive model: PBH = 0.026). No statistical significance was found between HSP90AA2 gene polymorphisms and GCs efficacy. These results revealed a genetic association between HSP90AA2 and SLE. Remarkably, HSP90AA2 has an impact on the improvement of HRQoL in Chinese population with SLE.